DelveInsight’s, “Thyroid Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Thyroid Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Thyroid Cancer Pipeline Outlook

 

Key Takeaways from the Thyroid Cancer Pipeline Report

• July 2024:- Istituti Clinici Scientifici Maugeri SpA– This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
• July 2024:- ModeX Therapeutics, An OPKO Health Company- A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors. This study consists of Phase 1a dose escalation, Phase 1b dose expansion in a single indication, and Phase 2a expansion in a single indication. This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
• DelveInsight’s Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
• The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
• Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.

 

Stay ahead with the most recent pipeline outlook for Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Thyroid Cancer Approved Drugs

 

Thyroid Cancer Emerging Drugs

• rhTSH: Suzhou Zelgen Biopharmaceuticals

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.

• Nivolumab: Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.

• RX208: Suzhou NeuPharma

RX208 is a potential “best-in-class” BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.

• AIC100: AffyImmune Therapeutics

AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.

 

Explore groundbreaking therapies and clinical trials in the Thyroid Cancer Pipeline. Access DelveInsight’s detailed report now! @ Thyroid Cancer Treatment Drugs

 

Thyroid Cancer Drugs and Companies

• Rosiglitazone: Exelixis
• Lenvatinib: Eisai Limited
• Ifosfamide: Merck Sharp & Dohme LLC

 

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Thyroid Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Unveil the future of Thyroid Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Thyroid Cancer Market Drivers and Barriers

 

Scope of the Thyroid Cancer Pipeline Report

• Coverage- Global
• Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
• Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Thyroid Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Thyroid Cancer Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Thyroid Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Thyroid Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. rhTSH: Suzhou Zelgen Biopharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nivolumab: Bristol-Myers Squibb
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AIC100:Affyimmune Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Thyroid Cancer Key Companies
21. Thyroid Cancer Key Products
22. Thyroid Cancer- Unmet Needs
23. Thyroid Cancer- Market Drivers and Barriers
24. Thyroid Cancer- Future Perspectives and Conclusion
25. Thyroid Cancer Analyst Views
26. Thyroid Cancer Key Companies
27. Appendix 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/